Skip to main content

The independent medical news service

21-01-2022 | Oncology | News | Article

ASCO/Ontario Health guideline on bone-modifying agents in breast cancer updated

Click through to find out what has changed

21-01-2022 | Oncology | News | Article

Capecitabine-containing adjuvant regimen improves early breast cancer OS

Adjuvant treatment with a capecitabine-containing chemotherapy regimen could improve the overall survival of patients with early breast cancer, suggest long-term follow-up data from the phase 3 FinXX trial.

14-01-2022 | Oncology | News | Article

10-year cumulative false–positive mammography risk around 20%

Just under one in five women will experience at least one false–positive result during 10 years of biennial breast screening, population-based data from Norway show.

10-01-2022 | Oncology | News | Article

GnRHa protects ovarian function during chemotherapy for breast cancer

Adding a gonadotropin-releasing hormone analog to cyclophosphamide-containing chemotherapy significantly reduces the risk for premature ovarian insufficiency in premenopausal women with breast cancer, Chinese research shows.

04-01-2022 | Oncology | News | Article

HER2CLIMB final OS analysis confirms tucatinib HER2-positive breast cancer benefit

The addition of tucatinib to trastuzumab plus capecitabine continues to confer an overall survival benefit in advanced HER2-positive breast cancer over longer follow-up, show phase 2 data.

21-12-2021 | Oncology | News | Article

NOS inhibitor shows potential for TNBC treatment

The pan-nitric oxide signaling inhibitor NG-monomethyl-l-arginine in combination with taxane merits further investigation in the locally advanced or metastatic triple-negative breast cancer setting, say researchers.